6. finer points of cell cycle control Flashcards
phosphorylation can be inhibitory or stimulatory, TRUE or FALSE?
TRUE
when cdk2 from G0 and late G1 phase is run on a gel what is seen? what does this suggest and how is it proved?
predominantly one band for cdk2 in G0 cells and two bands in the late G1 sample
>cdk2 has been phosphorylated, phosphatase can be used to revert late G1 phase cdk2 to single band
where is cdk2 phosphorylated? and how can this be identified?
the T loop (threonine loop)
> mass spectrometry
what is needed in order for Cdks to be active?
the phosphorylation of the T loop
describe the T loop when it is in-phosphorylated
its disordered
what happens to the T loop when cyclin E binds cdk2?
> the T loop becomes ordered
it undergoes conformational changes which make it more susceptible to phosphorylation
phosphorylation induces further conformational changes at opens up the active site
what phosphorylates the T loop of cdk2? and what is this not regulated by?
cyclin H/cdk7
this is not regulated by the cell cycle, it is always present and constantly active
although the T loop phosphorylation doesn’t result in a massive conformational change, what fold does it increase enzyme activity?
many thousand fold
what two functions does phosphorylation of the T loop have?
> promotes active site access - by removing T loop steric hindrance
promotes correct substrate alignment
what is the cdk phosphorylation consensus sequence?
S/TPxR/K
how does T loop phosphorylation promote correct substrate alignment?
> R and K carry a net positive charge at physiological pH
>the phosphorylation introduces a negative change which interacts with this
why is cyclin H/cdk7 a good anti-cancer target?
inhibiting it would stop the phosphorylation of cdks and could stop cell proliferation
what are the draw backs of using cyclinH/cdk7 inhibits as a therapeutic? and how can this be overcome?
that cyclin H/cdk7 is also required in the phosphorylation of the C terminal domain of RNA polymerase II, converting it from initiation phase to elongation phase of transcription - inhibiting it may abolish transcription
>there is a widow of opportunity to target T loop P over the transcriptional process, but even this still has off target effects
what was giving rise to Nurse’s Wee phenotype in fission yeast?
a lack of inhibitory phosphorylation which allows yeast to proliferate too fast
how do you screen for mutants in fission yeast?
> apply a mutagen to the system at a dose which mutates one gene per yeast
this is likely to be an inactivating mutation
what does wee1 do?
> phosphorylates cdks at two sites
> tyrosine 15 and threonine 14
what is odd about wee1 specificity?
it is unusual to have a kinase that can phosphorylate these two residues
what motif does wee1 phosphorylate? and where is this conserved motif found?
GxGxxG motif
>in the ceiling of the ATP binding site
where are the tyrosine and the threonine that are phosphorylated located? (cdks)
near the exit part of the ATP binding site
when the tyrosine and threonine are phosphorylated what does this result in? (cdks)
altered access of ATP and substrate to the ATP binding site
>blocks substrate recruitment
> substrates need to come into close proximity to the gamma phosphate
what is wee1 kinase activity physiologically important for? (2)
> to ensure that cdks are only active at the right stage.
>for growth arrest in response DNA damage
what enzyme removed the phosphate from inactive cdks? and what does this do?
cdc25
this activates the enzyme
when was cdc25 first defined?
in Nurse’s original screen in yeast - these enzymes are conserved in humans
why might cdc25 be a good potential therapeutic target?
it activates the cell cycle
>dual specificity phosphatase and so will be easier to drug as its unusual
how many different types of cdc25 are there and what are they called? and how are they implicated in cancer?
three
a, b and c
one of them is normally over expressed in cancer
what do cdc25 inhibitors target? and describe what many of the inhibitors have in common?
the active site cysteine
>many of these small inhibitors have a Quinone arrangement